GHP Investment Advisors Inc. Has $6.42 Million Stock Position in DaVita Inc. (NYSE:DVA)

GHP Investment Advisors Inc. trimmed its position in DaVita Inc. (NYSE:DVA - Free Report) by 4.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,937 shares of the company's stock after selling 2,146 shares during the quarter. GHP Investment Advisors Inc. owned approximately 0.05% of DaVita worth $6,415,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. United Capital Financial Advisors LLC lifted its position in shares of DaVita by 2.6% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock worth $361,000 after purchasing an additional 62 shares in the last quarter. Freedom Investment Management Inc. lifted its position in shares of DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after purchasing an additional 62 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of DaVita by 2.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock worth $531,000 after purchasing an additional 69 shares in the last quarter. UMB Bank n.a. lifted its position in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in shares of DaVita by 8.9% in the first quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock worth $148,000 after purchasing an additional 79 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DVA. Truist Financial cut their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research report on Monday, May 19th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $164.50.

DaVita Stock Up 0.4%

DVA traded up $0.61 during midday trading on Friday, hitting $141.70. 1,154,954 shares of the company's stock traded hands, compared to its average volume of 805,523. DaVita Inc. has a one year low of $131.76 and a one year high of $179.60. The company has a market cap of $10.70 billion, a PE ratio of 14.04, a price-to-earnings-growth ratio of 0.98 and a beta of 1.11. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. The stock's fifty day simple moving average is $139.46 and its 200-day simple moving average is $149.49.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter last year, the firm posted $2.26 earnings per share. The company's quarterly revenue was up 5.0% compared to the same quarter last year. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.